WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H327015
CAS#: 224624-80-0
Description: Miridesap (also known as Ro-638695, GSK-2315698, and CPHPC) is an antineoplastic which depletes circulating serum amyloid P component (SAP) almost completely but leaves some SAP in amyloid deposits for specific recognition by subsequently administered therapeutic anti-SAP antibodies. Since Miridesap removes SAP from the blood, it also removes SAP from the cerebrospinal fluid (CSF).
Hodoodo Cat#: H327015
Name: Miridesap
CAS#: 224624-80-0
Chemical Formula: C16H24N2O6
Exact Mass: 340.16
Molecular Weight: 340.376
Elemental Analysis: C, 56.46; H, 7.11; N, 8.23; O, 28.20
Synonym: Miridesap； Ro-638695； Ro 638695； Ro638695；GSK-2315698； GSK 2315698； GSK2315698；CPHPC；CPOHPC （acid form; CPOHPC acid
IUPAC/Chemical Name: (2'R)-adipoyldi-D-proline
InChi Key: InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1
InChi Code: InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1
SMILES Code: O=C(N1[C@H](CCC1)C(O)=O)CCCCC(N2[C@H](CCC2)C(O)=O)=O
Appearance: Solid powder
Purity: >97% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 340.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Al-Shawi R, Tennent GA, Millar DJ, Richard-Londt A, Brandner S, Werring DJ, Simons JP, Pepys MB. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo. Open Biol. 2016 Feb;6(2):150202. doi: 10.1098/rsob.150202. PubMed PMID: 26842068; PubMed Central PMCID: PMC4772805.
2: Sahota T, Berges A, Barton S, Cookson L, Zamuner S, Richards D. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 Feb;4(2):e15. doi: 10.1002/psp4.15. Epub 2015 Feb 4. PubMed PMID: 26225229; PubMed Central PMCID: PMC4360666.
3: Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med. 2015 Sep 17;373(12):1106-14. doi: 10.1056/NEJMoa1504942. Epub 2015 Jul 15. PubMed PMID: 26176329.
4: Lu GW, Shao G. Hypoxic preconditioning: effect, mechanism and clinical implication (Part 1). Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2014 Nov;30(6):489-501. PubMed PMID: 26016357.
5: Kolstoe SE, Jenvey MC, Purvis A, Light ME, Thompson D, Hughes P, Pepys MB, Wood SP. Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC). Acta Crystallogr D Biol Crystallogr. 2014 Aug;70(Pt 8):2232-40. doi: 10.1107/S1399004714013455. Epub 2014 Jul 25. PubMed PMID: 25084341; PubMed Central PMCID: PMC4118831.
6: Millar DJ, Hutchinson WL, Pepys MB. Immunoradiometric assay for human serum amyloid P component. J Immunol Methods. 2011 Aug 31;371(1-2):18-24. doi: 10.1016/j.jim.2011.06.010. Epub 2011 Jun 25. PubMed PMID: 21708157.
7: Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010 Nov 4;468(7320):93-7. doi: 10.1038/nature09494. Epub 2010 Oct 20. PubMed PMID: 20962779; PubMed Central PMCID: PMC2975378.
8: Kolstoe SE, Wood SP. Drug targets for amyloidosis. Biochem Soc Trans. 2010 Apr;38(2):466-70. doi: 10.1042/BST0380466. Review. PubMed PMID: 20298204.
9: Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010 Mar;148(5):760-7. doi: 10.1111/j.1365-2141.2009.08036.x. Epub 2010 Jan 8. PubMed PMID: 20064157.
10: Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23. doi: 10.1073/pnas.0902640106. Epub 2009 Apr 16. PubMed PMID: 19372378; PubMed Central PMCID: PMC2669789.
